The FDA has authorized use of the nirmatrelvir/ritonavir, for the treatment of mild to moderate COVID-19. Studies have indicated that it is 88% effective at preventing hospitalization and death from COVID-19. Criteria for Prescribing To prescribe nirmatrelvir/ritonavir, prescribers should confirm that the following criteria have been...

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America: Published on June 2022 COVID rebound has been reported to occur 2 to 8 days after initial recovery and is characterized by a recurrence of COVID-19 symptoms or a positive viral test after having tested negative. The CDC recommends that he...